ALK-Abello A/S is a pharmaceutical company based in Denmark that specializes in allergy prevention, diagnosis, and treatment. They focus on respiratory diseases such as allergic rhinitis and allergic asthma, as well as venom immunotherapy for bee and wasp allergies. Their treatments aim to provide long-term relief for allergy patients whose symptoms are not well controlled with standard medication. ALK-Abello operates in Europe, North America, and other international markets, with a strong revenue base in Europe. With a low ESG risk rating score of 19.3, ALK-Abello A/S is a reliable choice for those seeking pharmaceutical solutions for allergies.